Arzneimittelforschung 2012; 62(04): 181-186
DOI: 10.1055/s-0031-1299746
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Tissue Distribution Study of Naringin in Rats by Liquid Chromatography-Tandem Mass Spectrometry

W. Zou*
1   Guangdong Key Laboratory of Plant Resources, School of Life Sciences, Sun Yat-sen University, Guangzhou, P. R. China
,
C. Yang*
1   Guangdong Key Laboratory of Plant Resources, School of Life Sciences, Sun Yat-sen University, Guangzhou, P. R. China
,
M. Liu
1   Guangdong Key Laboratory of Plant Resources, School of Life Sciences, Sun Yat-sen University, Guangzhou, P. R. China
2   Guangdong Medi-world Pharmaceutical Co., Ltd., Foshan, P. R. China
,
W. Su
1   Guangdong Key Laboratory of Plant Resources, School of Life Sciences, Sun Yat-sen University, Guangzhou, P. R. China
› Author Affiliations
Further Information

Publication History

received 11 August 2011

accepted 19 December 2011

Publication Date:
23 January 2012 (online)

Abstract

Naringin (CAS 10236-47-2), a flavanone glucoside widely present in fruits of citrus plants, has received extensive studies on its potential effects on health benefits and was recently demonstrated to be a putative antitussive. In this study, we determined the tissue distributions of naringin and its metabolites (naringenin and naringenin’s conjugates) in rats to examine whether they undergo selective uptake by specific organs. Naringin was administered orally to rats at the dose of 42 mg/kg and the concentrations of naringin and its metabolites in tissue compartments were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The areas under curve values in the individual tissues decreased as follows: stomach, small intestine, liver, trachea, muscle, kidney, lung, fat, heart, spleen, ovary, testis, brain for naringin; and liver, stomach, small intestine, kidney, trachea, lung, testis, heart, ovary, fat, spleen, muscle, brain for total naringenin (including free and its conjugates). Naringin and total naringenin were rapidly and widely distributed to all the tissues except brain in rats. They had difficulties in crossing the blood-brain barrier. There are no accumulations in rats. This study identifying naringin in several organs including lung and trachea may explain its effects as antitussive.

*

*  These authors contributed equally to this work.


 
  • References

  • 1 Lambev I, Krushkov I, Zheliazkov D et al. Antiexudative effect of naringin in experimental pulmonary edema and peritonitis. Eksp Med Morfol 1980; 19 (04) 207-212
  • 2 Chen YT, Zheng RL, Jia ZJ et al. Flavonoids as superoxide scavengers and antioxidants. Free Radic Biol Med 1990; 9 (01) 19-21
  • 3 Martin MJ, Marhuenda E, Perez-Guerrero C et al. Antiulcer effect of naringin on gastric lesions induced by ethanol in rats. Pharmacology 1994; 49 (03) 144-150
  • 4 Lee CH, Jeong TS, Choi YK et al. Anti-atherogenic effect of citrus flavonoids, naringin and naringenin, associated with hepatic ACAT and aortic VCAM-1 and MCP-1 in high cholesterol-fed rabbits. Biochem Biophys Res Commun 2001; 284 (03) 681-688
  • 5 Schindler R, Mentlein R. Flavonoids and vitamin E reduce the release of the angiogenic peptide vascular endothelial growth factor from human tumor cells. J Nutr 2006; 136 (06) 1477-1482
  • 6 Gao S, Li PB, Yang HL et al. Antitussive effect of naringin on experimentally induced cough in Guinea pigs. Planta Med 2011; 77 (01) 16-21
  • 7 Mazzone SB. An overview of the sensory receptors regulating cough. Cough 2005; 1: 2
  • 8 Dicpinigaitis PV. Current and future peripherally-acting antitussives. Respir Physiol Neurobiol 2006; 152 (03) 356-362
  • 9 Liu Y, Su WW, Nie YC et al. Naringin attenuates acute lung injury in LPS-treated mice by inhibiting NF-kappaB pathway. Int Immunopharmacol 2011; 11 (10) 1606-1612
  • 10 Su WW, Wang YG, Fang TZ et al. Uses of naringenin, naringin and salts thereof as expectorants in the treatment of cough, and compositions thereof. European Patent 1591123
  • 11 Fang TZ, Wang YG, Ma Y et al. A rapid LC/MS/MS quantitation assay for naringin and its two metabolites in rats plasma. J Pharm Biomed Anal 2006; 40 (02) 454-459
  • 12 Felgines C, Texier O, Morand C et al. Bioavailability of the flavanone naringenin and its glycosides in rats. Am J Physiol Gastrointest Liver Physiol 2000; 279 (06) G1148-G1154
  • 13 Li XL, Xiao HB, Liang XM et al. LC-MS/MS determination of naringin, hesperidin and neohesperidin in rat serum after orally administrating the decoction of Bulpleurum falcatum L. and Fractus aurantii . J Pharm Biomed Anal 2004; 34 (01) 159-166
  • 14 Wang MJ, Chao PDL, Hou YC et al. Pharmacokinetics and conjugation metabolism of naringin and naringenin in rats after single dose and muliple dose administration. J Food Drug Anal 2006; 14: 247-253
  • 15 Mata-Bilbao ML, Andres-Lacueva C, Roura E et al. Absorption and pharmacokinetics of grapefruit flavanones in beagles. Br J Nutr 2007; 98 (01) 86-92
  • 16 Hsiu SL, Huang TY, Hou YC et al. Comparison of metabolic pharmacokinetics of naringin and naringenin in rabbits. Life Sci 2002; 70 (13) 1481-1489
  • 17 Food and Drug Administration . Guidance for Industry: Bioanalytical Method Validation. Rockville, MD: US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research; 2001
  • 18 O’Leary KA, Day AJ, Needs PW et al. Flavonoid glucuronides are substrates for human liver beta-glucuronidase. FEBS Lett 2001; 503 (01) 103-106